# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Jason Mills maintains TransMedics Gr (NASDAQ:TMDX) with a Buy and raises the price target from $10...
TD Cowen analyst Joshua Jennings maintains TransMedics Gr (NASDAQ:TMDX) with a Buy and raises the price target from $100 to ...
TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-...
JP Morgan analyst Allen Gong maintains TransMedics Gr (NASDAQ:TMDX) with a Overweight and raises the price target from $105 ...